MedDay, a biotechnology company focused on the treatment of nervous system disorders, reports additional positive data from its pivotal Phase III clinical trial, MS-SPI, with MD1003, a highly-concentrated pharmaceutical grade biotin, in patients with Progressive Multiple Sclerosis.

Read More:
MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

Scroll to Top